For the Pfizer/BioNTech and Moderna vaccines, this means that small changes were ... Previously, VSD identified a statistical ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial ...

FILE: Pfizer, left, and Moderna bivalent COVID-19 vaccines are readied for use at a clinic, Nov. 17, 2022, in Richmond, Va. The latest COVID-19 wave of infections across South Florida and the ...

Studies have shown these vaccines to be effective, with the Pfizer, GSK, and Moderna vaccines preventing ... strains of the RSV virus, called bivalent vaccines, may provide longer protection.

FDA Approvals and Expansions In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and ...

The vaccine approved for emergency authorization is manufactured by pharmaceutical company Novavax, with updated vaccines from Pfizer and Moderna available for use ... “It’s not bivalent, which is the ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

who added that the new vaccine also seems to achieve a more durable response than Moderna's first bivalent shot mRNA-1273.211, based on the original SARS-CoV-2 and the Beta variant. With Omicron ...

This year, instead of bivalent shots, both Pfizer and Moderna are monovalent. Both aim to protect against the Omicron subvariant KP.2, which circulated at high levels earlier this year. Both vaccines ...

Studies have shown these vaccines to be effective, with the Pfizer, GSK, and Moderna vaccines preventing ... strains of the RSV virus, called bivalent vaccines, may provide longer protection.

For the Pfizer/BioNTech and Moderna vaccines ... VSD identified a statistical signal for the Pfizer/BioNTech bivalent vaccine in 2022-2023 in people 65 years and older, but numerous other studies ...